BIOCRYST PHARMACEUTICALS, INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- BIOCRYST PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2020-06-30 was $92.85M.
- BIOCRYST PHARMACEUTICALS, INC. stock issued during period, value, new issues for the quarter ending 2018-09-30 was $53.40M.
- BIOCRYST PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- BIOCRYST PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2022 was $3.00K, a 99.99% decline from fiscal 2021.
- BIOCRYST PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2021 was $45.73M, a 50.98% decline from fiscal 2020.
- BIOCRYST PHARMACEUTICALS, INC. stock issued during period, value, new issues for fiscal 2020 was $93.28M, a 59.45% increase from fiscal 2019.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2025-02-25 | |
| 2022-12-31 | $3.00K 10-K · filed 2025-02-25 | |
| 2021-12-31 | $45.73M 10-K · filed 2024-02-27 | |
| 2020-12-31 | $93.28M 10-K · filed 2023-02-27 | |
| 2020-06-30 | $92.85M 10-Q · filed 2021-11-04 | |
| 2019-12-31 | $58.50M 10-K · filed 2022-02-28 | |
| 2018-12-31 | $53.40M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $53.40M 10-Q · filed 2019-11-08 | |
| 2017-12-31 | $134.00M 10-K · filed 2020-03-13 | |
| 2014-12-31 | $106.60M 10-K · filed 2017-02-27 | |
| 2013-12-31 | $23.63M 10-K · filed 2016-02-26 | |
| 2012-12-31 | $18.81M 10-K · filed 2015-03-02 | |
| 2011-12-31 | $1.03M 10-K · filed 2014-03-10 | |
| 2010-12-31 | $5.83M 10-K · filed 2013-03-11 | |
| 2009-12-31 | $45.74M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |